Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Spear Bio logo — The first homogeneous immunoassay platform offering unmatche...

Spear Bio

The first homogeneous immunoassay platform offering unmatched sensitivity with scalable simplicity.

Founded 2021 United States Boston, United States 32 employees Seed Biotechnology, Health Care

General Information

Company Name Spear Bio
Founded Year 2021
Location United States Boston, United States
Employees 32
Industries Biotechnology, Health Care
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Spear Bio. To contact Spear Bio, visit spear.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Spear Bio compare?

A PDF of Spear Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Spear Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Spear Bio

Spear Bio is a biotechnology startup focused on advancing lifescience research and clinical development by enabling laboratories to perform ultrasensitive immunoassays. The company was founded in 2021 and is headquartered in the United States. Spear Bio is tapping into a growing market need for ultrasensitive immunoassays in smaller samples, offering a platform based on technology licensed from Harvard University. This innovative platform has the capability to detect single-digit counts of proteins per sample in minuscule sample volumes, aiming to develop high-impact immunoassays that can be easily adopted by academic and clinical researchers and practitioners. In November 13, 2023, the company successfully closed its Seed Round investment, securing funding from notable investors including CDH Investments, Maverick Global Ventures, Sequoia China, and Yonghua. This investment aligns with Spear Bio's vision to revolutionize ultrasensitive immunoassays and signifies confidence from prominent players in the investment community. Spear Bio's dedication to addressing the growing demand for advanced immunoassay technologies, coupled with its strategic partnerships and prominent investor interest, positions the company as a promising contender in the Biotechnology and Health Care industries. With the support of its recent investors, Spear Bio is well-positioned to make significant strides in the field of ultrasensitive immunoassays and carve a niche for itself within the life sciences sector.

Business keywords: lifescience research, clinical development, ultrasensitive immunoassay, laboratory technology, Harvard University, protein detection, academic research, clinical research, technology licensing, biomedical innovation, research laboratories, biomedical diagnostics, biomarker detection, biomedical technology

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 4
CDH Investments Maverick Global Ventures 上海涌铧投资管理有限公司
CDH Investments, Maverick Global Ventures +2
13 Nov 2023

Spear Bio Alternatives & Competitors

View All Alternatives
Spear Bio vs
Rules-Based Medicine, an IQVIA business
Rules-Based Medicine, an IQVIA business United States

Industry leader in innovative biomarker solutions; specialty immunoassays using minimal sample volum...

Series A
155 employees
Biotechnology, Health Care
Spear Bio vs
Applied BioCode, Inc.
Applied BioCode, Inc. United States

The Ideal Choice for Cost-Effective High Throughput Syndromic Panels

Venture round
60 employees
Biotechnology, Health Care
Spear Bio vs
Diagnostics Biochem Canada (DBC)
Diagnostics Biochem Canada (DBC) Canada

Develop and market unique immunoassay kits that make a difference in the field of diagnostics and in...

43 employees
Biotechnology, Health Care
View all alternatives

FAQ About Spear Bio

The first homogeneous immunoassay platform offering unmatched sensitivity with scalable simplicity.
Spear Bio was founded in 2021.
Spear Bio is headquartered in Boston, United States.
Spear Bio operates in Biotechnology and Health Care. Its work centres on lifescience research, clinical development, ultrasensitive immunoassay and laboratory technology.
Spear Bio has approximately 32 employees.
Spear Bio has completed 1 funding round. The latest funding stage is Seed.
Top alternatives and competitors to Spear Bio include Rules-Based Medicine, an IQVIA business, Applied BioCode, Inc., Diagnostics Biochem Canada (DBC), SomaScan, Inoviv. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Spear Bio and Rules-Based Medicine, an IQVIA business are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Spear Bio, https://bouncewatch.com/company/spear-bio, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes